Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

Dimitrios A. Tsakiris, MD, Johannes Oldenburg, Robert Klamroth, Benoît Guillet, Kate Khair, Angela Huth-Kühne, MD, Karin Kurnik, Stephan Regensburger, Jaco Botha, Alejandro Fernandez, Leilei Tang, Margareth C. Ozelo

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139873

Published: 2020

Journal Articles

The Management of Cardiovascular Diseases in Patients with Hemophilia: The French Coche Registry

Benoit Guillet, Benedicte Wibaut, Céline Falaise, Aurelien Lebreton, Sabine Castet, Philippe Gautier, Ségolène Claeyssens, Jean-François Schved, Guillaume Cayla

Blood (2018) 132 (Supplement 1): 5018.

https://doi.org/10.1182/blood-2018-99-119656

Published: 2018

Journal Articles

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hervé Chambost, Ségolène Claeyssens-Donadel, Roseline d’Oiron, Véronique Goulet, Benoît Guillet, Virginie Héritier, Vanessa Milien, Chantal Rothschild, Valérie Roussel-Robert, Christine Vinciguerra, Jenny Goudemand

Blood (2014) 124 (23): 3398–3408.

https://doi.org/10.1182/blood-2014-07-586347

Published: 2014

Includes: Supplemental data

Journal Articles

Acquired Hemophilia Associated with Smoldering Myeloma: Demonstration That the Monoclonal Gammopathy Acts as the Factor VIII Inhibitor.

Olivier Decaux, Benoit Guillet, Arnaud Millet, Stephen Harding, Arthur R. Bradwell, Bernard Grosbois, Patrick Jego

Blood (2009) 114 (22): 1307.

https://doi.org/10.1182/blood.V114.22.1307.1307

Published: 2009

Journal Articles

Polymorphisms in TNFA and CTLA-4 Genes and the Risk of Heparin Induced Thrombocytopenia.

Dorothee Leroux, Claire Pouplard, PharmD, PhD, Benoit Guillet, MD, PhD, Beatrice Cosne, Marc Antoine May, MD, Yves Gruel, MD

Blood (2008) 112 (11): 3414.

https://doi.org/10.1182/blood.V112.11.3414.3414

Published: 2008

NARROW

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

The Management of Cardiovascular Diseases in Patients with Hemophilia: The French Coche Registry

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Acquired Hemophilia Associated with Smoldering Myeloma: Demonstration That the Monoclonal Gammopathy Acts as the Factor VIII Inhibitor.

Polymorphisms in TNFA and CTLA-4 Genes and the Risk of Heparin Induced Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

The Management of Cardiovascular Diseases in Patients with Hemophilia: The French Coche Registry

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Acquired Hemophilia Associated with Smoldering Myeloma: Demonstration That the Monoclonal Gammopathy Acts as the Factor VIII Inhibitor.

Polymorphisms in TNFA and CTLA-4 Genes and the Risk of Heparin Induced Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only